

Andras G Lacko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1997244/publications.pdf>

Version: 2024-02-01

73
papers

2,455
citations

218592

26
h-index

206029

48
g-index

73
all docs

73
docs citations

73
times ranked

2678
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel HDL mimicking targeted drug delivery system for the treatment of Ewing Sarcoma. FASEB Journal, 2022, 36, .	0.2	0
2	Pharmacological Modulation of B16â€F10 Murine Melanomaâ€Induced TAMs Functional Phenotype via Lipoproteinâ€Based Nanoparticles. FASEB Journal, 2022, 36, .	0.2	0
3	Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles Using Intrinsic Fluorescence. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 113-121.	1.3	5
4	Lipoproteins and the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1272, 93-116.	0.8	1
5	The SR-B1 Receptor as a Potential Target for Treating Glioblastoma. Journal of Oncology, 2019, 2019, 1-10.	0.6	18
6	Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene, 2019, 38, 6095-6108.	2.6	40
7	[^{99m} Tc-HYNIC-N-dodecylamide]: a new hydrophobic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimaging. Nanoscale, 2019, 11, 541-551.	2.8	18
8	Reâ€polarization of tumorâ€associated macrophages via reconstituted highâ€density lipoprotein nanoparticles. FASEB Journal, 2019, 33, .	0.2	1
9	Lipoproteins for therapeutic delivery: recent advances and future opportunities. Therapeutic Delivery, 2018, 9, 257-268.	1.2	21
10	Scavenger receptor class B type 1 regulates neuroblastoma cell proliferation, migration and invasion. Biochemical and Biophysical Research Communications, 2018, 495, 614-620.	1.0	17
11	Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy. Frontiers in Pharmacology, 2018, 9, 1154.	1.6	47
12	Fluorescence properties of doxorubicin in PBS buffer and PVA films. Journal of Photochemistry and Photobiology B: Biology, 2017, 170, 65-69.	1.7	80
13	SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer. Breast Cancer: Targets and Therapy, 2017, Volume 9, 383-392.	1.0	9
14	Ultrasound-Stimulated Drug Delivery Using Therapeutic Reconstituted High-Density Lipoprotein Nanoparticles. Nanotheranostics, 2017, 1, 440-449.	2.7	20
15	Superparamagnetic reconstituted high-density lipoprotein nanocarriers for magnetically guided drug delivery. International Journal of Nanomedicine, 2017, Volume 12, 1453-1464.	3.3	29
16	Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging. Frontiers in Pharmacology, 2016, 7, 466.	1.6	99
17	Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent. Journal of Photochemistry and Photobiology B: Biology, 2016, 155, 60-65.	1.7	22
18	HDL as a drug and nucleic acid delivery vehicle. Frontiers in Pharmacology, 2015, 6, 247.	1.6	61

#	ARTICLE	IF	CITATIONS
19	A homodimeric BODIPY rotor as a fluorescent viscosity sensor for membrane-mimicking and cellular environments. <i>Physical Chemistry Chemical Physics</i> , 2014, 16, 27037-27042.	1.3	61
20	Targeted Nanoparticles for Pediatric Leukemia Therapy. <i>Frontiers in Oncology</i> , 2014, 4, 101.	1.3	18
21	The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer. <i>Pharmaceutics</i> , 2013, 5, 353-370.	2.0	29
22	The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. <i>Frontiers in Pharmacology</i> , 2013, 4, 119.	1.6	250
23	Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma. <i>Frontiers in Pediatrics</i> , 2013, 1, 6.	0.9	26
24	Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. <i>Therapeutic Delivery</i> , 2012, 3, 599-608.	1.2	43
25	Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. <i>International Journal of Nanomedicine</i> , 2012, 7, 975.	3.3	41
26	Targeted Delivery of Small Interfering RNA Using Reconstituted High-Density Lipoprotein Nanoparticles. <i>Neoplasia</i> , 2011, 13, 309-IN8.	2.3	191
27	Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). <i>Drug Delivery and Translational Research</i> , 2011, 1, 113-120.	3.0	17
28	Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. <i>Journal of Drug Targeting</i> , 2010, 18, 53-58.	2.1	117
29	Studies on solvatochromic properties of aminophenylstyryl-quinolinium dye, LDS 798, and its application in studying submicron lipid based structure. <i>Biophysical Chemistry</i> , 2010, 153, 61-69.	1.5	17
30	Binding of 8-anilino-1-naphthalenesulfonate to lecithin:cholesterol acyltransferase studied by fluorescence techniques. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2008, 92, 19-23.	1.7	11
31	Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. <i>Anti-Cancer Drugs</i> , 2008, 19, 183-188.	0.7	112
32	Recent Developments and Patenting of Lipoprotein Based Formulations. <i>Recent Patents on Drug Delivery and Formulation</i> , 2007, 1, 143-145.	2.1	4
33	Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. <i>Expert Opinion on Drug Delivery</i> , 2007, 4, 665-675.	2.4	74
34	Trojan Horse Meets Magic Bullet to Spawn a Novel, Highly Effective Drug Delivery Model. <i>Chemotherapy</i> , 2006, 52, 171-173.	0.8	32
35	Characterization of lecithin:cholesterol acyltransferase expressed in a human lung cell line. <i>Protein Expression and Purification</i> , 2004, 36, 157-164.	0.6	5
36	Cardiovascular risk factors in Mexican-American children at risk for type 2 diabetes mellitus (T2DM). <i>Journal of Adolescent Health</i> , 2004, 34, 290-299.	1.2	21

#	ARTICLE	IF	CITATIONS
37	High density lipoprotein complexes as delivery vehicles for anticancer drugs. <i>Anticancer Research</i> , 2002, 22, 2045-9.	0.5	74
38	Probing the 121â€“136 Domain of Lecithin:Cholesterol Acyltransferase Using Antibodies. <i>Archives of Biochemistry and Biophysics</i> , 2001, 385, 267-275.	1.4	10
39	High cholesterol diet down regulates the activity of activator protein-1 but not nuclear factor-kappa B in rabbit brain. <i>Life Sciences</i> , 2001, 68, 1495-1503.	2.0	16
40	Apolipoprotein D in the aging brain and in Alzheimerâ€™s dementia. <i>Neurological Research</i> , 2000, 22, 330-336.	0.6	88
41	Dietary Fat Modulates Serum Paraoxonase 1 Activity in Rats. <i>Journal of Nutrition</i> , 2000, 130, 2427-2433.	1.3	72
42	Hyperbaric Oxygen Reduces the Progression and Accelerates the Regression of Atherosclerosis in Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1637-1643.	1.1	47
43	Fatty Acids Modulate Lecithin:Cholesterol Acyltransferase Secretion Independently of Effects on Triglyceride Secretion in Primary Rat Hepatocytes. <i>Journal of Nutrition</i> , 1998, 128, 1270-1275.	1.3	16
44	EVALUATION OF GEMFIBROZIL THERAPY. <i>American Journal of Therapeutics</i> , 1997, 4, 301-310.	0.5	5
45	Purification of Recombinant Lecithin:Cholesterol Acyltransferase. <i>Protein Expression and Purification</i> , 1997, 10, 38-41.	0.6	6
46	Effects of Simvastatin on Plasma Lipids and Apolipoproteins in Familial Hypercholesterolemic Swine. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 137-143.	1.1	21
47	The metabolism of high-density lipoproteins. <i>Trends in Cardiovascular Medicine</i> , 1994, 4, 84-88.	2.3	9
48	The Effect of Captopril on the Oxidation of Plasma Lipoproteins. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1994, 75, 218-221.	0.0	7
49	Decreased lecithin: Cholesterol acyltransferase activity in the plasma of hypercholesterolemic pigs. <i>Lipids</i> , 1992, 27, 266-269.	0.7	8
50	Age related changes in the lipoprotein substrates for the esterification of plasma cholesterol in rats. <i>Mechanisms of Ageing and Development</i> , 1991, 61, 85-98.	2.2	6
51	Study of the components of reverse cholesterol transport in lecithin: Cholesterol acyltransferase deficiency. <i>Archives of Biochemistry and Biophysics</i> , 1987, 258, 545-554.	1.4	17
52	The catalytic center of lecithin: Cholesterol acyltransferase: Isolation and sequence of diisopropyl fluorophosphate-labeled peptides. <i>Biochemical and Biophysical Research Communications</i> , 1987, 143, 360-363.	1.0	9
53	Age-related changes in the rate of esterification of plasma cholesterol in Fischer-344 rats. <i>Mechanisms of Ageing and Development</i> , 1986, 33, 211-220.	2.2	10
54	Purification of biologically active apolipoproteins by chromatofocussing. <i>Biomedical Applications</i> , 1986, 381, 271-283.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Isolation, characterization, and assay of lecithin-cholesterol acyltransferase. <i>Methods in Enzymology</i> , 1986, 129, 763-783.	0.4	88
56	Age-related changes in plasma lipid levels and tissue lipoprotein lipase activities of Fischer-344 rats. <i>Archives of Gerontology and Geriatrics</i> , 1985, 4, 133-140.	1.4	21
57	Evaluation of Lipid and Lipoprotein Metabolism in Rats as a Model for Studying Age-related Physiological Changes. <i>Journal of Gerontology</i> , 1984, 39, 513-520.	2.0	12
58	Lecithin: cholesterol acyltransferase in Down's syndrome. <i>Clinica Chimica Acta</i> , 1983, 132, 133-141.	0.5	15
59	Characterization of lecithin-cholesterol acyltransferase from human plasma. 3. Chemical properties of the enzyme. <i>Canadian Journal of Biochemistry and Cell Biology</i> , 1983, 61, 875-881.	1.3	29
60	Characterization of lecithin:cholesterol acyltransferase from human plasma: Purification of the enzyme. <i>Archives of Biochemistry and Biophysics</i> , 1981, 211, 119-124.	1.4	20
61	A test for the biochemical efficiency of isotopic cholesterol. <i>Lipids</i> , 1980, 15, 983-985.	0.7	4
62	A Novel Chromatographic Method for the Preparation of High Density Lipoproteins. <i>Preparative Biochemistry and Biotechnology</i> , 1980, 10, 431-444.	0.4	9
63	Age-Related Changes in Rat and Primate Plasma Cholesterol Metabolism. <i>Journal of the American Geriatrics Society</i> , 1979, 27, 212-217.	1.3	23
64	The influence of age and sex on the esterification of human serum cholesterol. <i>Biochemical Medicine</i> , 1977, 17, 275-283.	0.5	4
65	Enzyme purification by affinity chromatography using a non-covalently bound adsorbent. <i>Journal of Chromatography A</i> , 1977, 130, 446-450.	1.8	7
66	Factors affecting the esterification of lipoprotein cholesterol by lecithin: Cholesterol acyl transferase. <i>Life Sciences</i> , 1976, 18, 701-706.	2.0	9
67	On the interpretation and potential diagnostic value of the measurements related to lecithin:cholesterol acyltransferase activity. <i>Clinical Biochemistry</i> , 1976, 9, 212-215.	0.8	13
68	Serum cholesterol esterification in species resistant and susceptible to atherosclerosis. <i>Atherosclerosis</i> , 1974, 19, 297-305.	0.4	49
69	Serum cholesterol esterification in patients with coronary heart disease. <i>American Heart Journal</i> , 1973, 85, 153-161.	1.2	52
70	Measurement of the initial rate of serum cholesterol esterification. <i>Biochemical Medicine</i> , 1973, 7, 178-183.	0.5	50
71	Recovery of labeled cholesterol and cholesterol esters from thin layer chromatograms. <i>Clinica Chimica Acta</i> , 1972, 39, 506-510.	0.5	24
72	On the rate of cholesterol esterification in cord blood serum. <i>Lipids</i> , 1972, 7, 426-429.	0.7	30

#	ARTICLE	IF	CITATIONS
73	A monomeric form of procarboxypeptidase A from the spiny pacific dogfish. Biochemical and Biophysical Research Communications, 1967, 26, 272-277.	1.0	7